CONTEXT THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CONTEXT THERAPEUTICS INC. (CNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.74 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-05
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.89, a 173.91% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.69, a 17.86% decline year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.84, a 29.23% increase year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.65, a 51.13% decline year-over-year.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $3.84, a 58.89% decline from fiscal 2020.
- CONTEXT THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $9.34.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.74 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $1.89 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | $0.65 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.65 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $0.69 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $1.19 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $0.94 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $0.84 10-Q · filed 2025-05-07 | |||
| 2023-09-30 | $0.65 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $0.65 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $0.65 10-Q · filed 2024-05-08 | |||
| 2022-09-30 | $1.38 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $1.36 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $1.33 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $3.84 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $3.76 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $3.76 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $0.95 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $9.34 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $9.34 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |